Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab

por Thudium, Kent, Selby, Mark, Zorn, Julie A., Rak, Gregory, Wang, Xi-Tao, Bunch, Roderick Todd, Hogan, Jason M., Strop, Pavel, Korman, Alan J.
Publicado 2022